Neogi, Tuhina published the artcileObserved efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study, Name: 4-(5-(p-Tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, the publication is Arthritis Research & Therapy (2022), 24(1), 78, database is CAplus and MEDLINE.
A recent phase 3 study demonstrated that treatment with tanezumab, a nerve growth factor inhibitor, or nonsteroidal anti-inflammatory drugs (NSAIDs) improves pain and phys. function in participants with moderate-to-severe osteoarthritis (OA) of the hip or knee. Here, we evaluated the time course and clin. importance of these initial efficacy findings using a mixture of primary, secondary, and post hoc endpoints. Participants on stable NSAID therapy and with a history of inadequate response to other standard OA analgesics were enrolled in an 80-wk (56-wk treatment/24-wk safety follow-up), randomized, NSAID-controlled, phase 3 study primarily designed to assess the safety of tanezumab for moderate-to-severe OA of the knee or hip. Participants received oral NSAID (twice daily naproxen, celecoxib, or diclofenac) or s.c. tanezumab (2.5mg or 5mg every 8 wk). Non-responders were discontinued at week 16. Changes from baseline in WOMAC Pain and Phys. Function, Patients Global Assessment of Osteoarthritis (PGA-OA), and average pain in the index joint were compared between tanezumab and NSAID groups over the 56-wk treatment period. Clin. meaningful response (e.g., ≥30% and ≥50% improvement in WOMAC Pain and Phys. Function), rescue medication use, and safety were also assessed. All groups improved WOMAC Pain, WOMAC Phys. Function, PGA-OA, and average pain in the index joint over the 56-wk treatment period relative to baseline. Across all groups, improvements generally occurred from the time of first assessment (week 1 or 2) to week 16 and then slightly decreased from week 16 to 24 before stabilizing from weeks 24 to 56. The magnitude of improvement and the proportion of participants achieving ≥30% and ≥50% improvement in these measures was greater (unadjusted p≤0.05) with tanezumab than with NSAID at some timepoints on or before week 16. Adverse events of abnormal peripheral sensation, prespecified joint safety events, and total joint replacement surgery occurred more frequently with tanezumab than with NSAID. Tanezumab and NSAID both provided early and sustained (up to 56 wk) efficacy relative to baseline. Improvements in pain and function were clin. meaningful in a substantial proportion of participants. Adverse events of abnormal peripheral sensation and joint safety events occurred more frequently with tanezumab than with NSAID. Trial registration: ClinicalTrials.govNCT02528188. Registered on 19 July 2015.
Arthritis Research & Therapy published new progress about 169590-42-5. 169590-42-5 belongs to amides-buliding-blocks, auxiliary class Sulfamide,Immunology/Inflammation,COX, name is 4-(5-(p-Tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, and the molecular formula is C17H14F3N3O2S, Name: 4-(5-(p-Tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide.
Referemce:
https://en.wikipedia.org/wiki/Amide,
Amide – an overview | ScienceDirect Topics